[1]陈力,李静,吴奇.丹参酮ⅡA磺酸钠联合阿托伐他汀钙对冠心病心力衰竭的影响[J].西部中医药,2019,32(02):103-106.
 CHEN Li,LI Jing,WU Qi.Effects of Sodium TanshinonⅡA Silate Joined with Atorvastatin on Coronary Heart Disease Heart Failure[J].Western Journal of Traditional Chinese Medicine,2019,32(02):103-106.
点击复制

丹参酮ⅡA磺酸钠联合阿托伐他汀钙对冠心病心力衰竭的影响
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
32
期数:
2019年02期
页码:
103-106
栏目:
出版日期:
2019-02-15

文章信息/Info

Title:
Effects of Sodium TanshinonⅡA Silate Joined with Atorvastatin on Coronary Heart Disease Heart Failure
文章编号:
1004-6852(2019)02-0103-04
作者:
陈力李静吴奇
成都医学院第一附属医院,四川 成都 610500
Author(s):
CHEN LiLI JingWU Qi
The First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, China
关键词:
冠心病心力衰竭丹参酮ⅡA磺酸钠阿托伐他汀心功能氧化应激
Keywords:
coronary heart disease heart failure sodium tanshinonⅡA silate atorvastatin heart function oxidative stress
分类号:
R541.4
文献标志码:
B
摘要:
目的:观察丹参酮ⅡA磺酸钠联合阿托伐他汀治疗冠心病心力衰竭的临床疗效。方法:将64例冠心病心力衰竭患者随机分为对照组和观察组,各32例,对照组予阿托伐他汀钙,10 mg/次,1次/d;观察组在对照组的基础上给予丹参酮ⅡA磺酸钠注射液80 mg+5%葡萄糖注射液250 mL静脉滴注,1次/d。2组均于治疗4周后,观察临床疗效、不良反应及治疗前后心功能、氧化应激、血管活性物质水平的变化情况。结果:总有效率观察组为87.50%,对照组为62.50%,2组比较差异有统计学意义(P<0.05)。每分钟排血量(CO)、心脏指数(CI)、左心室射血分数(LVEF)、左心室舒张末期内径(LVEDd)、超氧化物歧化酶(SOD)、丙二醛(MDA)、一氧化氮(NO)、血管内皮生长因子(VEGF)、内皮素1(ET-1)、血管性血友病因子(VWF)等指标治疗前后2组组内比较,差异有统计学意义(P<0.05);治疗后2组组间比较差异也有统计学意义(P<0.05)。不良反应发生率观察组为6.25%,对照组为12.50%,2组比较差异无统计学意义(P>0.05)。结论:丹参酮ⅡA磺酸钠联合阿托伐他汀钙治疗冠心病心力衰竭患者临床疗效显著,安全性高,可改善心功能,这可能与抑制氧化应激反应、改善血管内皮功能有关。
Abstract:
Objective:To observe clinical effects of sodium tanshinonⅡA silate joined with atorvastatin in treating coronary heart disease heart failure. Methods:All 64 patients were randomly allocated to the control group and the observation group, 32 cases each group, the control group were treated by atorvastatin, 10 mg each time, once each day; the observation group received intravenous dripping of sodium tanshinonⅡA silate injection, 80 mg and 5% dextrose injection, 250mL, once each day, on the foundation of the therapy the control group accepted. The levels of vaso-active substance, oxidative stress, heart function before and after treating, adverse reaction and clinical effects of both groups were observed after they were treated for four weeks. Results: Total effective rate of the observation group was 87.50%, higher than 62.50% of the control group, and the difference was statistically significant (P<0.05). The difference had statistical meaning in the comparisons of cardiac output (CO), cardiac index (CI), left ventricular ejection fraction (LVEF), left ventricular end diastolic dimension (LVEDd), SOD, MDA, NO, VEGF, ET-1 and VWF within two groups before and after treating (P<0.05); the difference had statistical meaning in the comparisons between both groups after treating (P<0.05). The incidence of adverse reaction of the observation group was 6.25%, lower than 12.50% of the control group, and the difference had no statistical meaning (P>0.05). Conclusion: Sodium tanshinonⅡA silate joined with atorvastatin is effective in treating coronary heart disease heart failure with high safety, which could improve cardiac function, and this might be related to inhibiting oxidative stress reaction and improving vascular endothelial function.

相似文献/References:

[1]马思清 指导:谢春毅.瓜蒌薤白三方防治冠心病的研究现状[J].西部中医药,2012,25(10):118.
 MA Si-qing Director: XIE Chun-yi.Exploration on Three Pieces of GuaLou XieBaiFang in the Prevention of Coronary Heart Disease[J].Western Journal of Traditional Chinese Medicine,2012,25(02):118.
[2]潘雪晖.综合护理干预对冠心病患者不良生活方式的影响[J].西部中医药,2013,26(07):105.
 PAN Xuehui.Impact of Comprehensive Nursing Intervention on Lifestyles of Patients with Coronary Heart Disease[J].Western Journal of Traditional Chinese Medicine,2013,26(02):105.
[3]宋吉法.ACEI、ARB联合参松养心胶囊治疗慢性心力衰竭42例疗效观察[J].西部中医药,2012,25(07):63.
 SONG Ji-fa.Observation on Clinical Effects of ACEI and ARB Combined with ShenSong YangXin Capsule in Treating 42 Cases of Congestive Heart Failure[J].Western Journal of Traditional Chinese Medicine,2012,25(02):63.
[4]袁春玲.家庭病床冠心病护理可行性探讨[J].西部中医药,2012,25(07):109.
 YUAN Chun-ling.Probe into Feasibility of Nursing for Patients with Coronary Heart Disease in Family Practice[J].Western Journal of Traditional Chinese Medicine,2012,25(02):109.
[5]王凯,林文.丹红与丹参酮ⅡA治疗冠心病心绞痛疗效比较[J].西部中医药,2013,26(08):88.
 WANG Kai,LIN Wen.Comparison between DanHong Injection and Tanshinone ⅡA in Treating Angina Pectoris of Patients with Coronary Heart Disease[J].Western Journal of Traditional Chinese Medicine,2013,26(02):88.
[6]赵云霞,刘正跃.综合护理干预对冠心病患者不良生活方式的影响[J].西部中医药,2012,25(05):105.
 ZHAO Yun-xia,LIU Zheng-yue.Effects of Comprehensive Nursing Intervention on Unhealthy Lifestyle of Patients with Coronary Heart Disease[J].Western Journal of Traditional Chinese Medicine,2012,25(02):105.
[7]王瑞福.调脂汤对冠心病PCI术后血液流变学及血脂的影响[J].西部中医药,2013,26(12):71.
 WANG Ruifu.Effects of TiaoZhi Tang on Blood Lipid and Rheology of the Patients with Coronary Heart Disease After PCI[J].Western Journal of Traditional Chinese Medicine,2013,26(02):71.
[8]孙文,谢春毅△.丹红注射液治疗冠心病心绞痛临床观察[J].西部中医药,2014,27(03):5.
 SUN Wen,XIE Chunyi.Clinical Observation on DanHong Injection in Treating Coronary Heart Disease Angina Pectoris[J].Western Journal of Traditional Chinese Medicine,2014,27(02):5.
[9]王盛强.辨证论治慢性心力衰竭临床观察[J].西部中医药,2014,27(06):78.
 WANG Shengqiang.On Treating Chronic Heart Failure by Syndrome Differentiation and Treatment[J].Western Journal of Traditional Chinese Medicine,2014,27(02):78.
[10]付伟光,齐振勇,李爱军,等.HCY、HS-CRP、LP(a)及 D- 二聚体联合检测在冠心病病程中动态检测意义的研究*[J].西部中医药,2014,27(08):148.
[11]刘玉霞,王亚红△,王硕仁,等.冠心病临床心力衰竭(阶段C)患者证治规律研究[J].西部中医药,2015,28(03):1.

备注/Memo

备注/Memo:
收稿日期:2018-07-20 作者简介:陈力(1982—),男,硕士学位,主管药师。研究方向:天然药物有效成分的药效学研究。
更新日期/Last Update: 2019-02-15